Group 1 - The conference call is hosted by Veradigm, featuring remarks from CEO Don Trigg and Interim Chief Officer Lee Westerfield [2][4] - The presentation includes forward-looking statements that are based on current expectations and involve risks and uncertainties [3] - The company does not commit to revising forward-looking statements based on new information or future events [3]

Veradigm Update Conference Call Summary Company Overview - **Company**: Veradigm (OTCPK:MDRX) - **Date of Call**: February 18, 2026 Key Points Strategic Objectives - The CEO outlined three strategic objectives: reset business strategy, recover market leadership with independent physician practices, and reignite profitable growth [4][10] - The "Reset, Recover, Reignite" plan is fully launched, with a focus on aligning with independent physician practices to strengthen retention and drive growth [4][10] Financial Performance - Revenue for 2025 is estimated to be between $584 million and $589 million, essentially flat compared to 2024, with a slight decline of 1% at the midpoint [19] - The Provider segment, generating the majority of recurring revenue, is estimated to have revenue between $463 million and $467 million, down 2% at the midpoint compared to the prior year [20] - The Payer and Life Sciences segment revenue is estimated to be between $121 million and $122 million, flat at the midpoint compared to 2024 [20] Operational Changes - Six low-revenue products will be discontinued to focus on growth bets with near-term revenue potential [5][41] - The company plans to broaden revenue cycle services and enhance its global R&D function, leveraging AI as a key growth driver [6][51] - A new Chief Product and Technology Officer was appointed to accelerate AI adoption in product development [6] Workforce and Organizational Changes - The company eliminated 15% of its workforce in 2025 to flatten organizational design and increase decision velocity [7] - Internal engagement survey results showed an increase in confidence in strategic direction from 68% to 84% after the company kickoff in January [9] Market Opportunities - The company launched integrated billing for Practice Fusion clients, addressing a significant demand among small practice clients [10] - New deals in the payer space, including a partnership with Sentara Health Plans, highlight the market opportunity with large health systems [12] - The life sciences business closed two deals with a total contract value exceeding $1 million, indicating growth potential in this segment [13] Cash Flow and Financial Health - The company remains net cash positive, with cash at $120 million and debt at $75 million as of year-end 2025 [21] - Cash decreased by $174 million during 2025, primarily due to non-typical items such as debt financing activities and legal fees [21][22] SEC Filing Progress - The company is working to get current and stay current with SEC filings, with the next major milestone being the filing of the 2023/2024 Super K [15][25] - The launch of new IT systems under Project Atlas is critical for improving data integrity and contract standardization [14][25] Future Outlook - The CEO expressed optimism about the growth potential in 2026, emphasizing the importance of aligning with independent practices and enhancing revenue cycle management [34][36] - The company aims to leverage AI to improve operational performance and client engagement, particularly in revenue cycle areas [50][53] Conclusion - 2026 is viewed as a critical year for Veradigm, with a focus on resetting the business strategy, recovering financial performance, and reigniting growth [16][88]

Exhibit 99.1 Veradigm Provides Business and Strategy Update CHICAGO – February 17, 2026 – Veradigm® (OTCMKTS: MDRX), a leading provider of clinical and revenue cycle solutions for independent practices, is providing estimated financial performance for the fiscal year 2025 and key areas of strategic focus for 2026. "On my first investor call in October, I committed to advancing three strategic objectives in my first 100 days: reset our business strategy, recover our market leadership with independent physici ...

Core Insights - Veradigm has launched a new patient-reported outcomes (PRO) survey capability that integrates patient insights into real-world evidence generation, enhancing the context of clinical and observational research [1] - The solution is built on Veradigm's FollowMyHealth platform, allowing patients to securely share their experiences, which helps life sciences organizations gain a holistic view of patient experiences and outcomes [1] - The integration of patient-reported information with existing real-world data provides a fuller picture of symptom burden, treatment experience, adherence, and quality-of-life factors [1] Company Overview - Veradigm is a leading provider of clinical and revenue cycle solutions for independent practices, with a focus on improving outcomes and financial performance [1] - The company has a proven history of delivering AI-forward data and technology solutions that connect over 20,000 provider practices with health plans and biopharma [1] - Veradigm's solutions are designed to eliminate inefficiencies, close care gaps, and create a more affordable health system [1] Product Features - The new PRO survey capability includes integrated consent and compensation to reduce friction in patient participation [1] - It employs precision outreach to relevant patient groups and ensures trusted engagement through an established patient platform [1] - The solution aims to provide connected clinical and patient input for richer context, capturing patient-centered insights often missing from clinical documentation [1]

Core Insights - Veradigm announced enhancements to its AI-enhanced Ambient Scribe solution for EHR customers, showcasing its commitment to advanced AI solutions that improve clinical documentation and patient care [1] Company Developments - The Ambient Scribe solution has evolved significantly since its launch last year, indicating robust development and integration of AI technologies in healthcare [1]

Veradigm Investor Update Conference Call Summary Company Overview - **Company**: Veradigm - **Industry**: Healthcare Technology and IT Services Key Points Financial Performance - **Revenue Stability**: Revenue for Q2 2025 is estimated between $145 million and $148 million, reflecting a slight decrease of 2% year-over-year at the midpoint, and a year-to-date decrease of 1% at the midpoint [8][9] - **Recurring Revenue**: Approximately 79% of total revenue is recurring, consistent with the prior year [9] - **Provider Segment**: The largest segment, Provider revenue is estimated between $115 million and $117 million, down 3% year-over-year at the midpoint [9] - **Payer and Life Sciences Segment**: Revenue estimated between $30 million and $31 million, up 3% year-over-year at the midpoint [10] - **Cash Position**: As of June 30, 2025, cash on hand was $350 million, with debt at $283 million, resulting in a net cash positive position [13][17] Strategic Focus and Outlook - **2025 Outlook**: Revenue is expected to remain approximately flat compared to 2024, with a commitment to remain net cash positive throughout 2025 [19] - **SEC Filing Status**: The company aims to regain current filing status with the SEC by 2026, with ongoing audits for fiscal years 2023 and 2024 [20][21] - **Leadership Transition**: Don Trigg, the new CEO, emphasizes improving profitability, reigniting growth, and becoming current with SEC filings as top priorities [29][36] Growth Initiatives - **Revenue Cycle Management**: Recent contracts indicate momentum in revenue cycle services, with a three-year deal valued at $2.7 million signed in the Southeast [32] - **Payer Insights**: The company has deployed its gap in care closure solution, Veradigm Payer Insights, across 10,000 practices and over 35,000 providers [33] - **Life Sciences Data**: Veradigm offers a significant ambulatory patient data set for pharmaceutical research, enhancing its collaboration with organizations like the American College of Cardiology [34][35] Challenges and Opportunities - **Operational Challenges**: The company acknowledges challenges but also sees advantages in its established client base and strategic data assets [29][49] - **Market Position**: Veradigm's reputation in the marketplace is seen as an opportunity to enhance operational value for clients, particularly in practice operations and financial management [48][49] Future Plans - **Capital Investment Discipline**: Increased discipline around capital investment is planned to maximize returns [30][38] - **Operational Improvements**: The company is reviewing its product portfolio and operational systems to enhance growth and profitability [31][36] Closing Remarks - **Commitment to Progress**: The leadership expresses excitement about the future and the strategic potential of Veradigm, aiming for a relisting of common stock in 2026 [54] This summary encapsulates the key insights from the Veradigm Investor Update Conference Call, highlighting the company's financial performance, strategic focus, growth initiatives, challenges, and future plans.

[Company Overview and Strategic Direction](index=1&type=section&id=Company%20Overview%20and%20Strategic%20Direction) [Introduction and Key Updates](index=1&type=section&id=Introduction%20and%20Key%20Updates) Veradigm released Q2 2025 estimates, reaffirmed FY2025 outlook, and appointed Donald Trigg as CEO - Veradigm provided **Q2 2025 financial estimates**, details on **recent financing activities**, and **reaffirmed its FY2025 outlook**[1](index=1&type=chunk) - Donald Trigg joined Veradigm as **Chief Executive Officer and Board member** on **September 2, 2025**[2](index=2&type=chunk) [New Leadership and Strategic Vision](index=1&type=section&id=New%20Leadership%20and%20Strategic%20Vision) New CEO Donald Trigg outlined plans to boost profitability, revive growth, and ensure timely SEC filings - CEO Don Trigg outlined Veradigm's immediate path: **enhance profitability**, **revitalize growth**, and **timely complete SEC financial filings**[3](index=3&type=chunk) - The company possesses a **large national physician practice base** and **differentiated data assets** offering a 'mainstream health' perspective[3](index=3&type=chunk) [About Veradigm](index=2&type=section&id=About%20Veradigm) Veradigm is a healthcare technology company providing advanced insights and data-driven solutions - Veradigm is a healthcare technology company that creates value through its **unique combination of platform, data, expertise, connectivity, and scale**[9](index=9&type=chunk) - The Veradigm network provides **advanced insights, technology, and data-driven solutions** for healthcare providers, payers, and the biopharmaceutical market[9](index=9&type=chunk) [Second Quarter 2025 Financial Performance](index=1&type=section&id=Second%20Quarter%202025%20Financial%20Performance) [Preliminary Unaudited Financial Overview](index=1&type=section&id=Preliminary%20Unaudited%20Financial%20Overview) Veradigm reported preliminary Q2 2025 GAAP revenue of $145-$148 million, with $350M cash and $283M debt Financial Metrics Overview | Metric | Q2 2025 Estimate | YoY Change (Midpoint) | | :----- | :--------------- | :--------------------- | | Revenue (GAAP) | $145 million - $148 million | -2% | | Cash & Equivalents (as of Jun 30, 2025) | $350 million | Increase of ~$78M from Mar 31, 2025 | | Debt (as of Jun 30, 2025) | $283 million | | [Revenue Performance](index=4&type=section&id=Revenue%20Performance) Q2 2025 GAAP revenue projected at $145-$148 million, with provider revenue at $115-$117 million Revenue Breakdown | Revenue Segment | Q2 2025 (Estimate) | Q2 2024 | H1 2025 (Estimate) | H1 2024 | | :-------------- | :----------------- | :-------- | :----------------- | :-------- | | Provider Revenue (GAAP) | $115 million - $117 million | $119 million - $120 million | $228 million - $232 million | $234 million - $236 million | | Payer & Life Sciences Revenue (GAAP) | $30 million - $31 million | $29 million - $30 million | $61 million - $63 million | $58 million - $60 million | | **Total Veradigm Revenue (GAAP)** | **$145 million - $148 million** | **$148 million - $150 million** | **$289 million - $295 million** | **$292 million - $296 million** | [Cash and Debt Position](index=5&type=section&id=Cash%20and%20Debt%20Position) As of June 30, 2025, cash and equivalents totaled $350 million, up $78M from March 31, with total debt at $283M Cash and Debt Summary | Metric | Jun 30, 2025 | Dec 31, 2024 | | :----- | :------------ | :---------------- | | Cash & Cash Equivalents | $350 million | $294 million | | Debt | $283 million | $208 million | - Cash and equivalents increased by approximately **$78 million** from March 31, 2025, reflecting **$72 million in net debt financing inflows**, **$23 million in net portfolio activity inflows**, **$7 million in capital expenditure outflows**, and **$10 million in net operating activity outflows**[5](index=5&type=chunk) [Operational Highlights](index=2&type=section&id=Operational%20Highlights) Q2 2025 commercial team secured over $30 million in ACV, consistent with Q1, with stable revenue - The commercial team completed over **$30 million in annual contract value (ACV) transactions** in Q2 2025, consistent with Q1[7](index=7&type=chunk) - The interim CFO stated that **stable revenue performance** and a **robust capital base** are foundational pillars for the company's future success[7](index=7&type=chunk) [Financing Activities](index=1&type=section&id=Financing%20Activities) [Convertible Notes Repurchases](index=1&type=section&id=Convertible%20Notes%20Repurchases) Veradigm completed two convertible note repurchases totaling $230 million, reducing outstanding notes - On July 1, 2025, the company repurchased approximately **$180 million of convertible notes** using cash on hand, including **$164 million in principal** and **$16 million in contractual repurchase premium plus accrued interest**[5](index=5&type=chunk) - On September 29, 2025, the company repurchased approximately **$50 million of convertible notes** using cash on hand, including **$44 million in principal** and **$6 million in contractual repurchase premium plus accrued interest**[5](index=5&type=chunk) [Debt Structure Post-Repurchases](index=2&type=section&id=Debt%20Structure%20Post-Repurchases) Post-repurchases as of September 29, 2025, Veradigm's debt is primarily $75 million from a senior secured term loan - As of September 29, 2025, post-convertible note repurchases, the majority of the company's debt consists of **$75 million outstanding** under its senior secured term loan facility[6](index=6&type=chunk) - As of September 29, 2025, the company had **108.9 million common shares outstanding** and **10.6 million unvested restricted stock units**[6](index=6&type=chunk) [Fiscal Year 2025 Outlook](index=2&type=section&id=Fiscal%20Year%202025%20Outlook) [Reaffirmed Financial Expectations](index=2&type=section&id=Reaffirmed%20Financial%20Expectations) Veradigm reaffirmed FY2025 outlook, projecting GAAP revenue flat with FY2024 ($583-$588 million) and positive net cash FY 2025 Financial Outlook | Metric | FY 2025 Outlook | FY 2024 Estimate Range | | :----- | :------------------ | :---------------------- | | Revenue (GAAP) | Largely Flat | $583 million - $588 million | | Net Cash | Expected to Remain Positive | | [Investor Relations](index=2&type=section&id=Investor%20Relations) [Conference Call and Webcast Details](index=2&type=section&id=Conference%20Call%20and%20Webcast%20Details) Veradigm management will host an investor conference call and webcast on October 1, 2025, at 8:00 AM ET - Veradigm management plans to host an **investor conference call and webcast** on **October 1, 2025, at 8:00 AM ET**[7](index=7&type=chunk) - Participants can access the call via the **Veradigm Investor Relations website** or by dialing **877-405-1224** or **201-389-0848 (Access ID 13755960)**, with a replay available on the website for one year[8](index=8&type=chunk) [Legal and Forward-Looking Statements](index=3&type=section&id=Legal%20and%20Forward-Looking%20Statements) [Disclaimer on Preliminary Results](index=3&type=section&id=Disclaimer%20on%20Preliminary%20Results) Preliminary, unaudited financial estimates are subject to change upon completion of financial closing procedures - The financial performance estimates in this press release are **preliminary, unaudited results**, and final results may change upon completion of the company's financial closing procedures[12](index=12&type=chunk) [Forward-Looking Statements and Risk Factors](index=3&type=section&id=Forward-Looking%20Statements%20and%20Risk%20Factors) This release contains forward-looking statements based on management's beliefs, subject to risks like unlisted common stock, delayed reporting, internal control issues, SEC investigation, and litigation - This press release contains **forward-looking statements** based on management's current beliefs and expectations regarding future events, subject to **significant risks and uncertainties**[13](index=13&type=chunk) - Key factors that could cause actual results to differ materially from forward-looking statements include risks such as **common stock not trading on a national securities exchange**, **delayed financial reporting**, **internal control deficiencies**, **SEC investigation**, **litigation**, **leadership recruitment**, and **additional indebtedness**[14](index=14&type=chunk)

Core Points - Veradigm LLC experienced a data breach that was discovered around July 1, 2025, involving unauthorized access to customer data [1][3] - The breach likely exposed sensitive personal information, including names, Social Security numbers, contact details, dates of birth, health records, insurance information, payment data, and driver's license numbers [4] Company Overview - Veradigm LLC is a healthcare technology company that provides data-driven tools and solutions aimed at enhancing patient care and reducing healthcare costs [2] Incident Details - The data breach occurred around December 15, 2024, shortly after another security issue affected a different client of Veradigm [3] - The compromised storage account was the entry point for the unauthorized access to customer data [3] Legal Actions - Edelson Lechtzin LLP is investigating potential class action lawsuits for individuals whose sensitive personal data may have been compromised due to the breach [5]

Core Insights - Veradigm, previously known as Allscripts, has a long history in healthcare IT and has experienced multiple market cycles [1] - The company underwent rebranding in 2022 after selling its previous business [1] Company Overview - Veradigm is focused on identifying growth opportunities in the stock market while maintaining a reasonable price and strong economic moats [1] - The company emphasizes high-quality analysis, including valuations, key business drivers, risk/reward assessments, and various future scenarios [1]

Core Points - Veradigm LLC, a health information technology company, announced a cybersecurity incident affecting the personal information of tens of thousands of individuals [1] - The breach involved unauthorized access to personally identifiable information (PII) including names, contact details, dates of birth, health records, health insurance information, payment details, Social Security numbers, and driver's license numbers [1] Legal Implications - Lynch Carpenter, LLP is investigating claims against Veradigm related to the data breach, indicating potential legal actions for affected individuals [2] - Individuals who received a data breach notification from Veradigm may be entitled to compensation [2] Company Background - Lynch Carpenter is a national class action law firm with a focus on data privacy matters, representing millions of clients over more than a decade [3]